Stock comparison
AstraZeneca
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AZN
AstraZeneca
Market cap
$290.06B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AZN | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 63C | 69B | MTD |
| Benjamin Graham | 73B | 65B | AZN |
| Philip Fisher | 64C | 63C | AZN |
| Peter Lynch | 63C | 66B | MTD |
| Joel Greenblatt | 51C | 68B | MTD |
| Charlie Munger | 62C | 74B | MTD |
| Terry Smith | 60D | 70B | MTD |
Side-by-side metrics
| Metric | AZN | MTD |
|---|---|---|
| Market cap | $290.06B | $22.29B |
| P/E (TTM) | 27.6x | 25.3x |
| EV/EBIT | 23.0x | 21.6x |
| ROIC (TTM) | 12.88% | 36.09% |
| Gross margin | 79.71% | 57.79% |
| Net margin | 17.19% | 21.4% |
| Revenue CAGR 5y | 11.93% | 2.01% |
| EPS CAGR 5y | 2.01% | 6.12% |
| Debt / Equity | 0.7x | - |
| Dividend yield | 1.7% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AZN leads on
- Dividend yield1.7%vs 0.0%+100%
- EPS CAGR 5y2.01%vs 6.12%+97%
- Market cap$290.06Bvs $22.29B+92%
- Revenue CAGR 5y11.93%vs 2.01%+83%
MTD leads on
- Debt / Equity-vs 0.7x+101%
- ROIC (TTM)36.09%vs 12.88%+64%
- Net margin21.4%vs 17.19%+20%
- P/E (TTM)25.3xvs 27.6x+9%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.